The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nierkens, S.
Right arrow Articles by Pieters, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nierkens, S.
Right arrow Articles by Pieters, R.
The Journal of Immunology, 2002, 168: 3747-3754.
Copyright © 2002 by The American Association of Immunologists

Selective Requirement for CD40-CD154 in Drug-Induced Type 1 Versus Type 2 Responses to Trinitrophenyl-Ovalbumin1

Stefan Nierkens2,*, Pauline van Helden*, Marianne Bol*, Rob Bleumink*, Peter van Kooten{dagger}, Seema Ramdien-Murli{ddagger}, Louis Boon{ddagger} and Raymond Pieters*

* Department of Immunotoxicology, Institute for Risk Assessment Sciences, and {dagger} Immunology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands; and {ddagger} Tanox Pharma B.V., Amsterdam, The Netherlands

CD154 is transiently expressed by activated T cells and interacts with CD40 on B cells, dendritic cells, macrophages, and monocytes. This costimulatory receptor-ligand couple seems decisive in Ag-driven immune responses but may be differentially involved in type 1 vs type 2 responses. We studied the importance of CD40-CD154 in both responses using the reporter Ag popliteal lymph node assay in which selectively acting drugs generate clearly polarized type 1 (streptozotocin) or type 2 (D-penicillamine, diphenylhydantoin) responses to a constant coinjected Ag in the same mouse strain. Treatment of mice with anti-CD154 reduced characteristic immunological parameters in type 2 responses (B and CD4+ T cell proliferation, IgG1 and IgE Abs, and IL-4 secretion) and only slightly affected the type 1 response (small decrease in IFN-{gamma} production, influx of CD11c+ and F4/80+ cells, and prevention of architectural disruption of the lymph node, but no effect on IgG2a Ab and TNF-{alpha} secretion or B and CD4+ T cell proliferation). The findings indicate that the CD40-CD154 costimulatory interaction is a prerequisite in drug-induced type 2 responses and is only marginally involved in type 1 responses. The observed expression patterns of CD80 and CD86 on different APC (B cells in type 2 and dendritic cells in type 1) may be responsible for this discrepancy.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
F. A. Marshall and E. J. Pearce
Uncoupling of Induced Protein Processing from Maturation in Dendritic Cells Exposed to a Highly Antigenic Preparation from a Helminth Parasite
J. Immunol., December 1, 2008; 181(11): 7562 - 7570.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. P. Sanderson, D. J. Naisbitt, J. Farrell, C. A. Ashby, M. J. Tucker, M. J. Rieder, M. Pirmohamed, S. E. Clarke, and B. K. Park
Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling
J. Immunol., May 1, 2007; 178(9): 5533 - 5542.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. B. Carey, A. Allshire, and F. N. van Pelt
Immune Modulation by Cadmium and Lead in the Acute Reporter Antigen-Popliteal Lymph Node Assay
Toxicol. Sci., May 1, 2006; 91(1): 113 - 122.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Nierkens, M. Aalbers, M. Bol, R. Bleumink, P. van Kooten, L. Boon, and R. Pieters
Differential Requirement for CD28/CTLA-4-CD80/CD86 Interactions in Drug-Induced Type 1 and Type 2 Immune Responses to Trinitrophenyl-Ovalbumin
J. Immunol., September 15, 2005; 175(6): 3707 - 3714.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
F. van Wijk, S. Nierkens, I. Hassing, M. Feijen, S. J. Koppelman, G. A. H. de Jong, R Pieters, and L. M. J. Knippels
The Effect of the Food Matrix on In Vivo Immune Responses to Purified Peanut Allergens
Toxicol. Sci., August 1, 2005; 86(2): 333 - 341.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
S. Nierkens, M. Aalbers, M. Bol, F. van Wijk, I. Hassing, and R. Pieters
Development of an Oral Exposure Mouse Model to Predict Drug-Induced Hypersensitivity Reactions by Using Reporter Antigens
Toxicol. Sci., February 1, 2005; 83(2): 273 - 281.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
S. Nierkens, L. Nieuwenhuijsen, M. Thomas, and R. Pieters
Evaluation of the Use of Reporter Antigens in an Auricular Lymph Node Assay to Assess the Immunosensitizing Potential of Drugs
Toxicol. Sci., May 1, 2004; 79(1): 90 - 97.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Yasumi, K. Katamura, T. Yoshioka, T.-a. Meguro, R. Nishikomori, T. Heike, M. Inobe, S. Kon, T. Uede, and T. Nakahata
Differential Requirement for the CD40-CD154 Costimulatory Pathway during Th Cell Priming by CD8{alpha}+ and CD8{alpha}− Murine Dendritic Cell Subsets
J. Immunol., April 15, 2004; 172(8): 4826 - 4833.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Sharp, C. Thompson, E. T. Samy, R. Noelle, and K. S. K. Tung
CD40 Ligand in Pathogenesis of Autoimmune Ovarian Disease of Day 3-Thymectomized Mice: Implication for CD40 Ligand Antibody Therapy
J. Immunol., February 15, 2003; 170(4): 1667 - 1674.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.